Bayer Anticipates High-speed Growth After Merger (China)
This article was originally published in PharmAsia News
Executive Summary
Bayer Schering Pharmaceuticals China expects to maintain growth of over 30 percent in the market, as the merger of the healthcare units of Bayer and Schering nears completion. Liam Condon, managing director of Bayer Healthcare China and chief of Bayer Schering Pharmaceuticals China, reports Bayer Schering saw growth of about 50 percent in 2005 and is targeting a further 30 to 50 percent this year. "Our business scale (this year) will be much larger than last year's for sure," says Condon. U.S. healthcare industry research company IMS Health says that China's pharmaceutical market will grow by 14.4 percent this year. The Chinese pharmaceutical market is shifting focus from antibiotics to treatment for cancers, cardiovascular and cerebrovascular diseases, and diabetes. Bayer Schering also plans to introduce more of its blockbuster medicines to the Chinese market. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.